Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- Pediatric Physicians' Views On Religion, Spirituality
- Genetic Finding Could Lead To Targeted Therapy For Neuroblastoma
- Racial Differences In Risk Of Prostate Cancer Associated With Metabolic Syndrome
- ECCO-ESMO: Experimental Drug Matches Zoledronic Acid in Bone Mets (CME/CE)
- $691,930 Award Targets Brain Tumor Research
- New Or Not? Cracking Cyclic Natural Products For New Drugs
- Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
- Antigenics Therapeutics Limited Withdraws Its Marketing Authorisation Application For Oncophage (vitespen), Europe
- Penn Study Finds Loss Of Tumor-Suppressor And DNA-Maintenance Proteins Causes Tissue Demise
- Paul Marks Prize Recognizes Three Young Cancer Researchers
Prescription Cancer Drugs
Toward Bold New Anti-cancer Medicines
Posted by: admin in Prescription Cancer Drugs on November 07th, 2009
Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time, according to an article in the current issue of Chemical & Engineering News, ACS’ weekly newsmagazine.
C&EN Senior Editor Lisa Jarvis notes that “molecularly targeted” drugs are having a major impact in treating cancer of the breast, colon, and other body parts. Those medications interfere with specific molecules involved in cancer’s growth and spread. However, further advances are critical.
One new strategy involves cutting off cancer cells’ supply of blood sugar, or glucose, and thus starving them to death. Another uses RNA interference, a form of gene therapy in which short RNA segments serve as medication to block the genes involved in cancer. Although scientists face major hurdles in developing effective methods for administering RNA-based medicines, they are making rapid progress in doing so.
Source
Chemical & Engineering News